Ra-223 dichloride

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Breast CancerSarcoma

Phase 1

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

CompletedNCT01833520

M.D. Anderson Cancer CenterSarcoma

Start: 2013-10-16End: 2020-04-08Updated: 2021-02-02

Phase 2

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

CompletedNCT02366130

M.D. Anderson Cancer CenterBreast Cancer

Start: 2015-02-11End: 2020-12-16Updated: 2021-10-07

Related Papers

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Cancer Medicine2019-12-1831 citations

Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis

Cancer Research2019-02-151 citations

Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.

Journal of Clinical Oncology2018-05-206 citations

Abstract P1-16-02: Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis

Cancer Research2018-02-15

Alpha particle radium-223 dichloride (<sup>223</sup>RaCl<sub>2</sub> ) in high risk osteosarcoma.

Journal of Clinical Oncology2016-05-205 citations

Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma.

Journal of Clinical Oncology2014-05-205 citations